CD274 and neoplasm: Immune checkpoint blockade (ICB) therapy based on programmed death receptor (PD-1) and its ligand (PD-L1) can improve the host immune system's aggression against tumor cells by inhibiting the binding of PD-1 and PD-L1 [94].